Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
INREBIC Kaps 100 mg Ds 120 Stk
Drug
Inrebic, Hartkapseln
Primäre oder sekundäre Myelofibrose
07.16.1. – cytostatics
HAM – Human medicine
KAPS – Capsule
S – synthetic products for human use
A – Dispensed once only on prescription by a physician or veterinarian (A)
BA – Temporary approval expired
7/1/2021
2/28/2025
Dosage strength
Inrebic 100 mg, Hartkapseln
Primäre oder sekundäre Myelofibrose
01
BA – Temporary approval expired
Package
7680677920011
Out of trade from / since 11/7/2024
NA – No longer authorised
120 capsule(s)
001
BA – Temporary approval expired
Declaration
Component
100 mg fedratinibum
fedratinibi dihydrochloridum monohydricum
fedratinibi dihydrochloridum monohydricum
cellulosum microcristallinum silicificatum
natrii stearylis fumaras
0.18 mg natrium
gelatina
E 172 (rubrum)
E 171
lacca
E 171
propylenglycolum
natrii stearylis fumaras
0.18 mg natrium
gelatina
E 172 (rubrum)
E 171
lacca
E 171
propylenglycolum
Spezialitätenliste***
This package has been removed from the list of specialties. The displayed data correspond to the latest status.
SL
-
-
4850.00
None
Yes
10%
No
Authorisation holder
7601001010703
Bristol-Myers Squibb SA
Hinterbergstrasse 16
6312 Steinhausen (ZG)
Hinterbergstrasse 16
6312 Steinhausen (ZG)
Date of revision of the text
4/3/2025
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.